X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pibrentasvir (77) 77
glecaprevir (72) 72
hepatitis c (41) 41
hcv (39) 39
hepatitis c virus (37) 37
sofosbuvir (34) 34
index medicus (33) 33
gastroenterology & hepatology (27) 27
hepatitis (24) 24
patients (22) 22
efficacy (21) 21
antiviral agents (20) 20
pharmacology & pharmacy (20) 20
velpatasvir (19) 19
cirrhosis (18) 18
genotypes (18) 18
glecaprevir/pibrentasvir (18) 18
safety (18) 18
humans (17) 17
ribavirin (17) 17
infection (16) 16
genotype (15) 15
health aspects (15) 15
infections (15) 15
viruses (15) 15
interferon (14) 14
genotype 1 (13) 13
hcv genotype 1 (13) 13
therapy (13) 13
direct-acting antivirals (12) 12
hepatology (12) 12
ledipasvir (12) 12
medicine & public health (12) 12
open-label (12) 12
virus diseases (12) 12
antiviral agents - therapeutic use (11) 11
hepacivirus - genetics (11) 11
hepatitis c, chronic - drug therapy (11) 11
medical research (11) 11
microbiology (11) 11
care and treatment (10) 10
chronic infection (10) 10
gastroenterology (10) 10
antiretroviral drugs (9) 9
clinical trials (9) 9
combination (9) 9
daclatasvir (9) 9
hemodialysis (9) 9
hepacivirus - drug effects (9) 9
liver (9) 9
protease inhibitors (9) 9
virus genotype 1 (9) 9
6 infection (8) 8
colorectal surgery (8) 8
direct-acting antiviral (8) 8
drug therapy, combination (8) 8
genotype & phenotype (8) 8
infectious diseases (8) 8
medicine, experimental (8) 8
resistance (8) 8
treatment-naive (8) 8
voxilaprevir (8) 8
abdominal surgery (7) 7
benzimidazoles - therapeutic use (7) 7
compensated cirrhosis (7) 7
genetic aspects (7) 7
in-vitro (7) 7
liver cirrhosis (7) 7
liver diseases (7) 7
male (7) 7
prevalence (7) 7
quinoxalines - therapeutic use (7) 7
retreatment (7) 7
sulfonamides - therapeutic use (7) 7
surgical oncology (7) 7
abt-493 (6) 6
analysis (6) 6
antiviral drugs (6) 6
asunaprevir (6) 6
benzimidazoles - administration & dosage (6) 6
chronic hepatitis c (6) 6
digestive system diseases (6) 6
drug interactions (6) 6
drug therapy (6) 6
epidemiology (6) 6
hcv infection (6) 6
hepatitis-c virus (6) 6
hiv (6) 6
middle aged (6) 6
ns5a inhibitor (6) 6
pharmacokinetics (6) 6
proteases (6) 6
proteinase inhibitors (6) 6
public health (6) 6
quinoxalines - administration & dosage (6) 6
resistance-associated substitutions (6) 6
sulfonamides - administration & dosage (6) 6
sustained virologic response (6) 6
antiviral agents - administration & dosage (5) 5
biochemical phenomena, metabolism, and nutrition (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Internal Medicine, ISSN 0918-2918, 2019
Clinical trials and real-world data have proven that hepatitis C virus (HCV) in most infected patients can be eradicated by direct-acting antivirals (DAAs).... 
pibrentasvir | hemodialysis | HCV | retreatment | glecaprevir
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 03/2018, Volume 16, Issue 3, pp. 417 - 426
Hepatitis C virus (HCV) has high genotypic diversity and global distribution. Agents that are effective against all major HCV genotypes, with shorter treatment... 
Direct-acting Antiviral | Short-duration | DAA | Pangenotypic | GLECAPREVIR | VELPATASVIR | PIBRENTASVIR | NS5A | SOFOSBUVIR | ADULTS | HCV | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Internal Medicine, ISSN 0918-2918, 2019
The efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with human immunodeficiency virus (HIV) and/or genotype 3 hepatitis C virus (HCV)... 
hemophilia | HIV | pibrentasvir | HCV | genotype 3 | glecaprevir
Journal Article
JOURNAL OF GASTROENTEROLOGY, ISSN 0944-1174, 07/2019, Volume 54, Issue 7, pp. 660 - 666
BackgroundEfficacy of 8-week regimen with direct-acting antivirals (DAA) for patients with hepatitis C after liver transplantation has not been clarified. This... 
Pibrentasvir | INTERFERON-FREE THERAPY | SOFOSBUVIR | VIRUS GENOTYPE 1 | RIBAVIRIN | LEDIPASVIR | Glecaprevir | INCREASE | HCV | Hepatitis C | 6 INFECTION | GASTROENTEROLOGY & HEPATOLOGY | GLECAPREVIR/PIBRENTASVIR | Liver transplantation
Journal Article
International journal of antimicrobial agents, ISSN 0924-8579, 07/2019
This systematic review and meta-analysis investigated the efficacy and safety of glecaprevir and pibrentasvir (G/P) for chronic hepatitis C virus (HCV)... 
Journal Article
JOURNAL OF GENERAL VIROLOGY, ISSN 0022-1317, 07/2019, Volume 100, Issue 7, pp. 1123 - 1131
Combination therapy with glecaprevir (GLE) and pibrentasvir (PIB) has high efficacy for pan-genotypic hepatitis C virus (HCV)-infected patients. However, the... 
ASUNAPREVIR | human hepatocyte chimeric mouse | RIBAVIRIN | NS5A inhibitor resistance associated variant | REPLICATION | VIROLOGY | pibrentasvir | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | HCV | DACLATASVIR | 6 INFECTION | ANTIVIRAL DRUGS | SOFOSBUVIR-VELPATASVIR | GLECAPREVIR/PIBRENTASVIR | glecaprevir
Journal Article
Journal Article
Journal of Hepatology, ISSN 0168-8278, 08/2018, Volume 69, Issue 2, pp. 293 - 300
Glecaprevir plus pibrentasvir (G/P) is a pangenotypic, once-daily, ribavirin-free direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV)... 
Short duration | Hepatitis C | Pangenotypic | Direct-acting antiviral | GLECAPREVIR | HEPATITIS-C VIRUS | EFFICACY | PIBRENTASVIR | SAFETY | INFECTION | FUTURE DISEASE BURDEN | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Journal Article
Australian prescriber, ISSN 0312-8008, 10/2018, Volume 41, Issue 5, pp. 169 - 170
Journal Article
Gastroenterology research, ISSN 1918-2805, 06/2019, Volume 12, Issue 3, pp. 176 - 180
Treatment of hemodialysis patients infected with two or three hepatitis C virus (HCV) genotypes (Gt) with interferon-free regimens has not been possible until... 
Direct-acting antiviral agents | Glecaprevir | pibrentasvir | Hemodialysis | Recombinant 2k | Hepatitis C virus | Case Report | 1b genotype
Journal Article
Journal of Hepatology, ISSN 0168-8278, 05/2019, Volume 70, Issue 5, pp. 1019 - 1023
Curative treatment of patients who previously failed hepatitis C virus (HCV) therapies is critical to achieving HCV elimination. Glecaprevir/pibrentasvir (G/P)... 
Resistance | Retreatment | G/P | HCV | RAS | SOFOSBUVIR | OPEN-LABEL | RIBAVIRIN | HCV INFECTION | GENOTYPE 1 | VELPATASVIR | PIBRENTASVIR | CLINICAL-TRIALS | RESISTANCE-ASSOCIATED SUBSTITUTIONS | GASTROENTEROLOGY & HEPATOLOGY | ANTIVIRAL DRUGS | Hepatitis C
Journal Article
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, ISSN 1747-4124, 09/2019, Volume 13, Issue 9, pp. 839 - 848
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.